Central Brain Tumor Registry of the United States, Hinsdale, IL, USA.
Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.
Neuro Oncol. 2023 Oct 4;25(12 Suppl 2):iv1-iv99. doi: 10.1093/neuonc/noad149.
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.83 per 100,000 population (malignant AAAIR=6.94 and non-malignant AAAIR=17.88). This overall rate was higher in females compared to males (27.85 versus 21.62 per 100,000) and non-Hispanic persons compared to Hispanic persons (25.24 versus 22.61 per 100,000). Gliomas accounted for 26.3% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (14.2% of all tumors and 50.9% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (40.8% of all tumors and 56.2% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.13 per 100,000 population. There were 86,030 deaths attributed to malignant brain and other CNS tumors between 2016 and 2020. This represents an average annual mortality rate of 4.42 per 100,000 population and an average of 17,206 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.7%, for a non-malignant brain and other CNS tumor the five-year relative survival rate was 91.8%.
美国中央脑肿瘤登记处(CBTRUS)与疾病控制与预防中心和国家癌症研究所合作,是美国最大的专注于原发性脑肿瘤和其他中枢神经系统(CNS)肿瘤的基于人群的登记处,代表了整个美国人口。本报告包含了最新的基于人群的原发性脑肿瘤数据,在完整性和准确性方面超过了 CBTRUS 的所有先前报告。所有比率均使用 2000 年美国标准人口进行年龄调整,并以每 10 万人为单位呈现。所有恶性和非恶性脑和其他 CNS 肿瘤的平均年年龄调整发病率(AAAIR)为 24.83/10 万人(恶性 AAAIR=6.94,非恶性 AAAIR=17.88)。女性的总体发病率高于男性(每 10 万人 27.85 比 21.62),非西班牙裔人口高于西班牙裔人口(每 10 万人 25.24 比 22.61)。神经胶质瘤占所有肿瘤的 26.3%。最常见的恶性脑和其他 CNS 组织病理学是胶质母细胞瘤(占所有肿瘤的 14.2%,所有恶性肿瘤的 50.9%),最常见的主要非恶性组织病理学是脑膜瘤(占所有肿瘤的 40.8%,所有非恶性肿瘤的 56.2%)。胶质母细胞瘤在男性中更为常见,脑膜瘤在女性中更为常见。在儿童和青少年(0-19 岁)中,所有原发性脑和其他 CNS 肿瘤的发病率为 6.13/10 万人。2016 年至 2020 年期间,有 86030 人死于恶性脑和其他 CNS 肿瘤。这代表平均每年每 10 万人中有 4.42 人死亡,平均每年有 17206 人死亡。恶性脑和其他 CNS 肿瘤诊断后的五年相对生存率为 35.7%,非恶性脑和其他 CNS 肿瘤的五年相对生存率为 91.8%。
Acta Neuropathol. 2025-8-23
Neurooncol Adv. 2025-7-11
Clin Transl Radiat Oncol. 2025-8-8
CA Cancer J Clin. 2023-1
Neuro Oncol. 2021-8-2
Neurooncol Pract. 2019-12